1 2	Coronary Microvascular Function Following Severe Preeclampsia
3 4	Running Title: Microvascular Dysfunction in Preeclampsia
4 5 7 8 9 10 11 12	 Michael C. Honigberg, MD, MPP^{1,2}; Katherine E. Economy, MD, MPH³; Maria A. Pabón, MD⁴; Xiaowen Wang, MD, MPH⁴; Claire Castro, PhD¹; Jenifer M. Brown, MD^{4,5}; Sanjay Divakaran, MD^{4,5}; Brittany N. Weber, MD, PhD^{4,5}; Leanne Barrett⁵; Anna Perillo⁵; Anina Y. Sun⁵; Tajmara Antoine¹; Faranak Farrohi⁴; Brenda Docktor⁴; Emily S. Lau, MD, MPH¹; Doreen DeFaria Yeh, MD¹; Pradeep Natarajan, MD, MMSc^{1,2}; Amy A. Sarma, MD¹; Robert M. Weisbrod, MA⁶; Naomi M. Hamburg, MD, MS⁶; Jennifer E. Ho, MD⁷; Jason D. Roh, MD¹; Malissa J. Wood, MD^{1,8}; Nandita S. Scott, MD¹; Marcelo F. Di Carli, MD^{4,5}
13	1. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard
14 15	Medical School, Boston, MA 2. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,
16	MA
17 18	3. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
19	4. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's
20	Hospital, Harvard Medical School, Boston, MA
21 22	5. Cardiovascular Imaging Program, Departments of Radiology and Medicine, and Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's
23	Hospital, Harvard Medical School, Boston, MA
24	6. Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA
25 26	7. Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
20 27	8. Lee Health Heart Institute, Fort Myers, FL
28	
29	Address for Correspondence:
30	Michael C. Honigberg, MD, MPP
31	Massachusetts General Hospital
32	185 Cambridge Street CPZN 3.187
33	Boston, MA 02114
34	Phone: (617) 726-1843
35	Fax: (617) 726-2203
36	mhonigberg@mgh.harvard.edu
37	Twitter: @mchonig

- 37 Twitter: @mchonig
- 38
- **Word Count:** 4,013

40 Abstract

41 Background: Preeclampsia is a pregnancy-specific hypertensive disorder associated with an 42 imbalance in circulating pro- and anti-angiogenic proteins. Preclinical evidence implicates 43 microvascular dysfunction as a potential mediator of preeclampsia-associated cardiovascular

44 risk. 45

46 Methods: Women with singleton pregnancies complicated by severe antepartum-onset

47 preeclampsia and a comparator group with normotensive deliveries underwent cardiac positron

- 48 emission tomography (PET) within 4 weeks of delivery. A control group of pre-menopausal, non-
- 49 postpartum women was also included. Myocardial flow reserve (MFR), myocardial blood flow
- 50 (MBF), and coronary vascular resistance (CVR) were compared across groups. Soluble fms-like
- 51 tyrosine kinase receptor-1 (sFIt-1) and placental growth factor (PIGF) were measured at 52 imaging.
- 53

54 Results: The primary cohort included 19 women with severe preeclampsia (imaged at a mean

- 55 16.0 days postpartum), 5 with normotensive pregnancy (mean 14.4 days postpartum), and 13
- 56 non-postpartum female controls. Preeclampsia was associated with lower MFR (β =-0.67 [95%
- 57 CI -1.21 to -0.13]; P=0.016), lower stress MBF (β =-0.68 [95% CI, -1.07 to -0.29] mL/min/g;
- 58 P=0.001), and higher stress CVR (β =+12.4 [95% CI 6.0 to 18.7] mmHg/mL/min/g; P=0.001) vs.
- 59 non-postpartum controls. MFR and CVR after normotensive pregnancy were intermediate
- 60 between preeclamptic and non-postpartum groups. Following preeclampsia, MFR was positively associated with time following delivery (P=0.008). The sFIt-1/PIGF ratio strongly correlated with 61
- rest MBF (r=0.71: P<0.001), independent of hemodynamics. 62
- 63

64 Conclusions: In this exploratory study, we observed reduced coronary microvascular function in 65 the early postpartum period following severe preeclampsia, suggesting that systemic

- 66 microvascular dysfunction in preeclampsia involves the coronary microcirculation. Further
- 67 research is needed to establish interventions to mitigate risk of preeclampsia-associated
- 68 cardiovascular disease. 69
- 70

Abstract Word Count: 250

71

72 **Keywords:** preeclampsia: pregnancy: women's health: cardiac positron emission tomography:

73 coronary microvascular function

74 Abbreviations and Acronyms

- 75
- 76 BMI body mass index
- 77 CAD coronary artery disease
- 78 CVR coronary vascular resistance
- 79 HFpEF heart failure with preserved ejection fraction
- 80 MBF myocardial blood flow
- 81 MFR myocardial flow reserve
- 82 PET positron emission tomography
- 83 PIGF placental growth factor
- 84 PPCM peripartum cardiomyopathy
- 85 sFlt-1 soluble fms-like tyrosine kinase receptor 1

86 Introduction

87 Preeclampsia is a pregnancy-specific disorder characterized by new-onset or worsening 88 hypertension after 20 weeks' gestation accompanied by proteinuria or other end-organ 89 dysfunction.^{1,2} Up to 8% of child-bearing individuals in the U.S. experience preeclampsia in 1 or more pregnancies.³ Preeclampsia represents a leading cause of maternal and infant morbidity 90 91 and mortality both in the U.S. and globally, with potential maternal complications including 92 stroke, seizure, kidney injury, pulmonary edema, and peripartum cardiomyopathy (PPCM). In 93 addition, preeclampsia portends heightened long-term maternal risk of atherosclerotic cardiovascular disease and heart failure.4-9 94

95 The late-stage pathophysiology of preeclampsia is characterized by an excess of 96 circulating anti-angiogenic factors (e.g., soluble fms-like tyrosine kinase receptor 1 [sFIt-1] and 97 soluble endoglin) relative to pro-angiogenic factors (e.g., placental growth factor [PIGF] and vascular endothelial growth factor [VEGF]).¹⁰ This angiogenic imbalance leads to systemic 98 99 maternal endothelial dysfunction and vasoconstriction, which in turn causes hypertension, proteinuria, and other clinical manifestations of preeclampsia.¹¹ Women who develop 100 101 preeclampsia have reduced flow-mediated dilation, a marker of peripheral endothelial function, 102 in the antepartum setting, at the time of preeclampsia, and potentially up to several years postpartum.¹² In addition, severe preeclampsia has been associated with differences in cardiac 103 104 structure and function in the acute setting by echocardiography, including relatively impaired 105 diastolic function, reduced longitudinal strain, and increased left ventricular (LV) wall thickness compared with findings in normotensive pregnant individuals.¹³ Prior work indicates that higher 106 107 circulating sFlt-1 levels correlate with lower myocardial performance index (an integrated echocardiographic measure of systolic and diastolic function)¹⁴ and global longitudinal strain at 108 the time of preeclampsia diagnosis independent of blood pressure.¹⁵ Furthermore, 109 110 preeclampsia-associated coronary microvascular dysfunction has been postulated to contribute 111 to later-life cardiovascular disease, including heart failure with preserved ejection fraction

112 (HFpEF).¹⁶ Whether preeclampsia impacts peripartum coronary microvascular function,

113 however, has not been tested to date.

114 Myocardial flow reserve (MFR), calculated as the ratio of hyperemic myocardial blood 115 flow (MBF) to rest MBF, represents the integrated effects of epicardial coronary artery disease 116 (CAD) and microvascular vasomotor function; in the absence of obstructive epicardial CAD, 117 impairment in MFR reflects coronary microvascular dysfunction. MFR is reproducible and 118 prognostic, stratifying risk of major adverse cardiovascular events and of HFpEF in midlife and 119 elderly adults.^{17,18} Cardiac positron emission tomography (PET) represents the most extensively 120 validated non-invasive modality for assessment of coronary microvascular function.¹⁷ 121 Therefore, to determine the acute effects of severe preeclampsia on coronary 122 microvascular function, we prospectively enrolled a cohort of postpartum women and compared 123 PET-derived indices of MFR and MBF with values from pre-menopausal, non-postpartum 124 female controls. We hypothesized that MFR would be reduced after delivery in women with 125 preeclampsia. In addition, we assessed clinical, echocardiographic, and angiogenic biomarker 126 correlates of MFR and MBF among women with severe preeclampsia. 127

128 Methods

129 Study Cohorts

130 This study received human subjects approval from the Mass General Brigham 131 Institutional Review Board, and all participants provided written informed consent. Between 132 December 2020 and October 2022, we prospectively recruited and enrolled women aged ≥ 18 133 years delivering at Brigham and Women's Hospital and Massachusetts General Hospital, two 134 large academic medical centers in Boston, Massachusetts. Recruitment was conducted 135 principally during admission to the antepartum or postpartum obstetrical floors; normotensive 136 control subjects were additionally recruited from routine prenatal visits and via an online 137 research recruitment portal. Women with severe antepartum-onset preeclampsia were identified

according to American College of Obstetricians and Gynecologists (ACOG) criteria as those 138 with preeclampsia accompanied by severe hypertension (blood pressure ≥160/110 mmHg) after 139 140 20 weeks' gestation accompanied by proteinuria (300 mg/24 h collection, spot urine 141 protein/creatinine ratio ≥0.3 mg/dL, or urine dipstick with 2+ proteinuria) and/or accompanied by 142 other qualifying severe features (thrombocytopenia, renal insufficiency, liver function abnormalities, pulmonary edema, new-onset headache, or visual symptoms).¹⁹ Given potential 143 overlap in pathophysiology between preeclampsia and preterm birth,¹⁶ and in order to isolate 144 145 any potential effects, if present, specifically attributable to pregnancy, the healthy postpartum 146 comparator group included women who delivered at term (≥37 weeks' gestation) and who 147 lacked chronic hypertension, gestational hypertension, preeclampsia, or gestational diabetes. Exclusion criteria were body mass index \geq 50 kg/m² or history of epicardial CAD or coronary 148 149 artery dissection, valvular heart disease, or pre-existing cardiomyopathy prior to pregnancy. 150 Prospectively enrolled participants underwent PET imaging, transthoracic echocardiography, 151 and phlebotomy as part of a single study visit performed at Brigham and Women's Hospital as 152 soon as possible following delivery and no later than one month postpartum. Given prior 153 literature suggesting that normal cardiac remodeling and biomarker risk thresholds associated with adverse outcomes differ between singleton and twin pregnancies, 20,21 participants (n=3) 154 155 with twin gestations were excluded from the present analysis (Figure S1).

Measures of MBF and flow reserve by PET imaging in postpartum participants were compared with those from a control group of healthy, non-diabetic, pre-menopausal, nonpostpartum research participants enrolled in a prior study using identical methods for assessing myocardial perfusion with PET.²² Exclusion criteria included a history of uncontrolled hypertension, diagnosed cardiac or pulmonary disease, cerebrovascular or peripheral artery disease, or laboratory evidence of kidney or hepatic dysfunction.

162

164 Cardiac Positron Emission Tomography

165 Postpartum participants underwent measurement of MBF performed on a whole-body 166 PET-computed tomography scanner (Discovery MI, GE Healthcare, Milwaukee, WI) at rest and during vasodilator stress using ¹³N-ammonia or ⁸²Rb-rubidium as the flow tracer. Prior work 167 suggests high reproducibility across radiotracers.²³ The protocol was designed to ensure safety 168 169 and acceptability for newly postpartum individuals. Adenosine was used as the vasodilator 170 agent to minimize interruption of breastfeeding. Studies were performed after 4 hours of fasting 171 and at least 12 hours following last caffeine intake. Participants were generally advised to 172 withhold antihypertensive medications on the morning of the study visit; however, given the 173 inclusion of women with severe preeclampsia in the early postpartum period (a high-risk period for persistent hypertension and associated complications²⁴), we permitted participants to take 174 175 antihypertensive medications if deemed medically necessary by the study team or if requested 176 by either the participant or treating clinician and probed the potential influence of these 177 medications on study findings in sensitivity analyses. Non-postpartum controls underwent rest and adenosine-stress myocardial perfusion PET with ¹³N-ammonia.²² Absolute rest and 178 hyperemic MBF were calculated by fitting the ¹³N-ammonia or ⁸²Rb time-activity curves to a 179 validated two-compartment tracer kinetic model.²³ MFR was calculated as the ratio of hyperemic 180 181 to rest MBF. Coronary vascular resistance (CVR) was calculated as mean arterial pressure 182 divided by MBF. Analysis was performed with blinding to preeclampsia status.

183

184 Transthoracic Echocardiography

Echocardiography was performed on postpartum participants using GE E95 machines by experienced, licensed sonographers. Measures of left and right ventricular structure and function, left atrial size, and diastolic function were analyzed according to contemporary echocardiography guidelines.^{25,26} Additional details are provided in the **Supplemental Methods**.

190 Angiogenic Biomarkers

The ratio of sFIt-1 to PIGF reflects angiogenic balance in pregnancy, is validated among 191 192 pregnant individuals with suspected preeclampsia to "rule out" short-term progression to severe preeclampsia,²⁷ and was recently approved by the U.S. Food and Drug Administration to guide 193 194 obstetrical management. We assayed sFlt-1 and PIGF on venous blood serum drawn 195 immediately prior to PET imaging using enzyme-linked immunosorbent assays (R&D Systems, 196 Inc., Minneapolis, MN). 197 198 Outcomes 199 The primary study outcome was MFR as measured by cardiac PET imaging. Secondary

200 outcomes were MBF and CVR both at rest and with vasodilator stress.

201

202 Statistical Analysis

203 Participant characteristics were compared across study groups using analysis of 204 variance or the Kruskal-Wallis test for normally distributed and skewed continuous variables, 205 respectively, and using the Fisher exact test for categorical variables. Primary models used 206 unadjusted linear regression to calculate differences in PET indices (MFR, rest MBF, stress 207 MBF, rest CVR, and stress CVR) among preeclamptic postpartum and normotensive 208 postpartum participants vs. non-postpartum study participants (reference group). Given the 209 older age of non-postpartum controls vs. postpartum participants, we additionally calculated 210 differences in PET indices between groups with adjustment for age.

To probe robustness of our findings, we conducted sensitivity analyses that excluded women with pre-pregnancy chronic hypertension and gestational diabetes and further adjusted for BMI at the time of imaging. We additionally performed subgroup analyses that stratified women with preeclampsia (1) by delivery <34 weeks' vs. ≥34 weeks' gestation and (2) by whether women required antihypertensive medication on the morning of the study visit.

216 In exploratory analyses, we examined whether timing of imaging relative to delivery or 217 clinical characteristics/routine laboratory biomarkers used in the diagnosis or monitoring of 218 preeclampsia were associated with postpartum MFR, MBF, or CVR among individuals with 219 preeclampsia using unadjusted linear regression. In addition, we compared echocardiographic 220 parameters between women with preeclampsia and normotensive postpartum women 221 (reference group) using the Student's t-test or Wilcoxon rank-sum test, as appropriate. Pearson 222 correlation coefficients tested the relationship of with MFR and MBF with echocardiographic 223 indices among women with preeclampsia. In analyses of angiogenic biomarkers (sFIt-1, PIGF. 224 and the sFIt-1/PIGF ratio) measured at the time of PET imaging, we also used Pearson 225 correlation coefficients to test the relationship of log-transformed biomarkers with MFR, MBF, 226 and CVR. 227 Sample size was calculated based on prior literature of flow-mediated dilation in women 228 with preeclampsia¹² and on available PET measurements in healthy female controls to provide 229 80% power to detect a 20% difference in MFR among those with preeclampsia vs. non-230 postpartum controls with a two-sided alpha of 0.05. 231 Two-sided P<0.05 indicated statistical significance; findings from secondary and 232 exploratory analyses should be considered supportive and hypothesis-generating. Analyses 233 were performed in R version 4.3.1. 234 235 **Results** 236 The primary PET imaging cohort included 19 postpartum women with severe 237 preeclampsia (mean [SD] age 32.9 [2.8] years, 15.3 [7.6] days postpartum at study 238 assessment), 5 postpartum women following normotensive pregnancy (31.5 [3.6] years, 14.4 239 [8.4] days postpartum at assessment; Figure S2), and 13 non-postpartum pre-menopausal 240 female controls (40.1 [8.5] years at assessment; **Table 1**). Overall, 27 of 37 participants (73.0%) 241 were White, 5 (13.5%) were Black, 2 (5.4%) were Asian, and 3 (8.1%) were Hispanic. Of the 24

242 postpartum women studied. 15 (62.5%) were primiparous (i.e., had borne a total of one 243 offspring) at the time of the study assessment, with a similar distribution of parity between those 244 with preeclampsia and normotensive index pregnancies (Table 1). No participants had chronic 245 diabetes, and 1 participant with preeclampsia also had gestational diabetes. Among those with 246 preeclampsia in the index pregnancy, 4 (21.1%) had chronic pre-pregnancy hypertension with 247 superimposed preeclampsia, 6 (31.6%) had used low-dose aspirin for preeclampsia prevention, 248 and all but 1 (94.7%) delivered via Cesarean section. Participants with severe preeclampsia 249 were enriched for delivery before 34 weeks' gestation in the index pregnancy (14/19 [73.7%]). 250 and gestational age at delivery was earlier in those with preeclampsia vs. normotensive 251 pregnancy. Body mass index (BMI), SBP, DBP, and heart rate were each higher at the time of 252 study assessments in women with preeclampsia vs. both normotensive postpartum individuals 253 and non-postpartum controls (Table 1). 254 255 Association of Preeclampsia with Myocardial Flow Reserve, Myocardial Blood Flow, and

256 Coronary Vascular Resistance

257 The mean (SD) MFR was 2.82 (0.70) in women following delivery with preeclampsia. 258 3.14 (0.55) following normotensive pregnancy, and 3.49 (0.84) in non-postpartum controls. 259 Compared with values in non-postpartum individuals, preeclampsia was associated with lower 260 MFR (β =-0.67 [95% CI, -1.21 to -0.13]; *P*=0.016; **Figure 1**). The corresponding difference in 261 individuals following normotensive pregnancy was -0.35 (95% CI, -1.14 to +0.44; P=0.37). After 262 adjustment for age, preeclampsia and normotensive pregnancy were associated with 263 differences in MFR of -0.76 (95% CI, -1.39 to -0.14; P=0.018) and -0.47 (95% CI, -1.34 to +0.41; 264 P=0.29), respectively, vs. non-postpartum women (**Table 2**). 265 There were no significant differences in rest MBF in either the preeclampsia or 266 normotensive postpartum groups vs. non-postpartum controls (Table 2; Figure S3). However, 267 stress MBF was significantly reduced in both postpartum groups (preeclampsia: β =-0.68 [95%

CI, -1.07 to -0.29] mL/min/g; *P*=0.001; normotensive: β =-1.01 [95% CI, -1.58 to -0.43] mL/min/g; *P*=0.001). Compared with non-postpartum individuals, women with preeclampsia had higher rest CVR (β =+23.9 [95% CI, 1.3 to 46.5] mmHg/mL/min/g; *P*=0.04) and stress CVR (β =+12.4 [95% CI, 6.0 to 18.7] mmHg/mL/min/g; *P*<0.001), with values observed in normotensive postpartum individuals falling between those of the preeclamptic and non-postpartum groups (**Table 2**).

274 Differences in PET indices among women following preeclampsia vs. non-postpartum 275 controls were highly consistent in sensitivity analyses restricted to women without pre-276 pregnancy chronic hypertension or women without gestational diabetes (**Table S1**). In models 277 further adjusted for BMI at the time of imaging, estimated differences in MFR were similar but 278 estimated differences in stress MBF, rest CVR, and stress CVR for preeclamptic participants 279 were mildly attenuated compared with primary analyses (**Table S2**). Findings were also broadly 280 consistent in women with preeclampsia and delivery either before or after 34 weeks' gestation, 281 apart from a greater increase in rest CVR observed among those with delivery after 34 weeks 282 (Table S3).

Among women with preeclampsia, MFR was positively associated with the number of days postpartum at the time of PET imaging (0.05 [95% CI, 0.02 to 0.09] per day; P=0.008; **Figure 3A**). Rest MBF decreased with the number of days postpartum (-0.02 [95% CI, -0.04 to -0.004] per day; P=0.02; **Figure 3B**), whereas there was no apparent temporal relationship with stress MBF in the early postpartum period (**Table S4**).

Eight participants with preeclampsia (42.1%) required use of 1 or more antihypertensive medications on the morning of the study visit (7 used nifedipine, 4 used labetalol, and 1 used enalapril). Those who required antihypertensive medication completed study assessments closer to delivery than those who did not (median [IQR] 14.5 [8.3, 16.0] days postpartum vs. 19.0 [16.0, 20.5] days postpartum, respectively; P=0.10). Compared with non-postpartum

293	participants, MFR was lower by 0.84 (95% CI 0.10-1.49; P=0.01) in those who required
294	antihypertensive medication and lower by 0.55 (95% CI -0.12 to 1.22; P=0.10) in other
295	participants with preeclampsia. Those who took antihypertensive medication on the morning of
296	the study visit had attenuated differences in rest CVR compared with those who did not but had
297	similar differences in rest MBF, stress MBF, and stress CVR (Table S5).
298	
299	Clinical Correlates of Postpartum PET Indices in Women with Severe Preeclampsia
300	Maximum recorded antepartum SBP was nominally associated with reduced stress MBF
301	at postpartum PET imaging (β =-0.02 [95% CI, -0.03 to -0.001] mL/min/g per mmHg SBP;
302	P=0.04). Maximum recorded DBP, maximum recorded proteinuria, and other laboratory
303	biomarkers used to diagnose preeclampsia and its subtypes were each not significantly
304	associated with postpartum MFR or other PET indices (Table S6). Report of headache as part
305	of preeclampsia symptomatology vs. no reported headache was associated with reduced stress
306	MBF (β =-0.66 [95% CI -1.21 to -0.12] mL/min/g; <i>P</i> =0.02) and increased stress CVR (β =+11.8
307	[95% CI 2.8 to 20.9] mmHg/mL/g/min; <i>P</i> =0.01). BMI ≥30 kg/m² vs. <30 kg/m² at the time of PET
308	imaging was associated with reduced stress MBF (β =-0.72 [95% CI
309	-1.24 to -0.20] mL/min/g; <i>P</i> =0.01), increased rest CVR (<i>β</i> =+48.1 [95% CI 17.1 to 79.2]
310	mmHg/mL/g/min; <i>P</i> =0.02), and increased stress CVR (β =+14.9 [95% CI 7.3 to 22.5]
311	mmHg/mL/g/min; <i>P</i> <0.001) (Table S6). Hematocrit nadir during the delivery admission (mean
312	[SD] 28.3 [4.0]%) was not associated with any postpartum PET indices.
313	
314	Postpartum Echocardiographic Differences Between Groups and PET Correlates in Women
315	with Severe Preeclampsia
316	Transthoracic echocardiography was performed in 17 of the 19 enrolled postpartum
317	women with preeclampsia (mean [SD] 15.5 [7.9] days postpartum at study assessment) and in 7

318 women following normotensive pregnancy (13.7 [7.8] days postpartum at assessment; Figure 319 S1; Table S7). Compared with normotensive postpartum women, those with preeclampsia had 320 greater LV wall thickness (mean [SD] septal wall thickness: 8.9 [2.0] vs. 6.7 [0.4] mm; P<0.001; 321 posterior wall thickness: 9.1 [1.5] vs. 6.8 [1.0] mm; P<0.001) and greater relative wall thickness 322 (0.38 [0.07] vs. 0.30 [0.07]; P=0.03). LV ejection fraction did not differ between groups (Table 323 3). In addition, women with preeclampsia had reduced lateral e' velocity (13.7 [2.4] vs. 16.8 [2.1] 324 cm/s; P=0.008) and higher E/e' (median [IQR] 7.8 [6.6, 8.0] vs. 5.7 [5.0, 7.2]; P=0.04). Mean 325 (SD) left atrial volume was 55.7 (12.6) mL in participants with preeclampsia vs. 45.5 (10.5) mL 326 in those with normotensive pregnancy (P=0.06). Regional and global LV strain indices were 327 numerically higher in women with preeclampsia vs. normotensive pregnancy, although 328 differences did not reach statistical significance (Table 3). 329 In exploratory analyses, we did not observe any significant correlations between MFR 330 and echocardiographic parameters among women with severe preeclampsia (**Table S8**). 331 332 Postpartum Angiogenic Factor Levels and PET Indices in Women with Severe Preeclampsia 333 Among women with preeclampsia, the median [IQR] sFlt-1 level was 435.5 [388.6, 334 582.4] pg/mL, the PIGF level was 6.1 [5.2, 7.3] pg/mL, and the sFIt-1/PIGF ratio was 90.8 [62.2, 335 119.2] at the time of PET imaging. The sFIt-1/PIGF ratio declined exponentially with time 336 postpartum (Figure S4). The sFIt-1/PIGF ratio was moderately inversely correlated with MFR 337 (r=-0.45; P=0.05; Figure 4A; Table S9), driven by a stronger positive correlation with rest MBF 338 (r=0.71; P<0.001; Figure 4B) than with stress MBF (r=0.22; P=0.36). These correlations were 339 stronger after excluding participants who required antihypertensive medication on the morning 340 of imaging assessment (MFR: r=-0.80, P=0.003; rest MBF: r=0.91, P<0.001; Figure S5). In a 341 post hoc model mutually adjusted for both rate-pressure product and the sFlt-1/PIGF ratio, only 342 the sFIt-1/PGF ratio was independently associated with rest MBF (β =0.21 [95% CI, 0.05 to 0.37] 343 mL/min/g per log-unit; P=0.01).

344 Discussion

345 Coronary microvascular dysfunction has been hypothesized to underlie both acute and 346 longer-term cardiovascular morbidity in women with preeclampsia. To our knowledge, this 347 analysis represents the first interrogation of coronary blood flow and microvascular reactivity in 348 the peripartum period following preeclampsia. In line with our hypothesis, we observed a 349 reduction in the maximum adenosine-stimulated flow response and a related increase in CVR 350 following severe preeclampsia vs. the non-postpartum state. Furthermore, MFR appeared to 351 recover with time postpartum following preeclampsia due to normalization of rest flows: this 352 normalization of rest flow was tightly correlated with the sFIt-1/PIGF ratio, independent of 353 hemodynamics. Of note, normotensive postpartum participants also had significantly decreased 354 stress MBF and intermediate findings with respect to MFR, suggesting that a portion of 355 observed differences may reflect normal postpartum physiology that is compounded or 356 exaggerated in the context of preeclampsia. Taken together, these findings support the notion 357 that preeclampsia exerts adverse coronary microvascular effects and may have implications for 358 understanding risk of short-term (e.g., PPCM) and long-term cardiovascular complications in 359 affected women.

360 First, our findings reinforce the relevance of the microcirculation in preeclampsia. SFIt-1 361 is believed to exert its anti-angiogenic effects by binding to and blocking the pro-angiogenic properties of PIGF and VEGF.¹ In preclinical models, sFIt-1 blocks angiogenesis-associated 362 migration of endothelial cells¹⁴ and provokes constriction of rat renal arterioles.¹¹ The anti-363 364 angiogenic effects of sFlt-1 may represent a "second hit" triggering PPCM in susceptible 365 individuals and may therefore explain this condition's peak incidence in the very early postpartum period, immediately after circulating anti-angiogenic factor levels have peaked.^{14,28} A 366 367 recent investigation further reported that mice with sFlt-1 overexpression in pregnancy 368 demonstrated enhanced mesenteric vasoconstriction vs. wild-type mice in response to an 369 angiotensin II challenge at two months postpartum, implying potential enduring effects on

sensitivity to pro-hypertensive stimuli beyond the peripartum period.²⁹ Furthermore, human 370 studies have suggested microvascular rarefaction in the retina³⁰ and fingers³¹ of midlife women 371 372 with a history of preeclampsia, independent of blood pressure. Collectively, these findings imply 373 potential "microvascular susceptibility" in women with preeclampsia. Although our findings 374 suggested short-term improvement in MFR related to normalization of rest MBF with time 375 postpartum, ongoing coronary microvascular susceptibility following preeclampsia may contribute to the excess risk of HFpEF¹⁸ reported in affected women.^{7,9} Future longitudinal 376 377 studies will enable further interrogation of this hypothesis.

378 Second, placental biomarkers may provide insights regarding how preeclampsia affects 379 myocardial blood flow. Among women with severe preeclampsia in our study, the sFlt-1/PIGF 380 ratio correlated strongly with rest MBF. Furthermore, the correlation of sFIt-1/PIGF with rest 381 MBF among preeclamptic women was not explained by the rate-pressure product, suggesting 382 that preeclampsia exerts hemodynamic-independent effects on cardiomyocyte oxygen 383 utilization. Through feedback between cardiomyocytes and the coronary microcirculation, 384 coronary arterioles may dilate to increase MBF in the resting state to compensate for impaired 385 tissue oxygen extraction and/or utilization. Prior work demonstrates impaired oxygen utilization in the context of severe preeclampsia.^{32,33} The association of the sFlt-1/PIGF ratio with 386 387 increased rest MBF may therefore reflect an effort by cardiomyocytes to overcome 388 microvascular and/or cardiomyocyte dysfunction driven by circulating placental proteins. 389 Third, our findings highlight key gaps in understanding of cardiac effects in normal 390 pregnancy and normal postpartum cardiovascular adaptation. Reduction in stress MBF in both 391 hypertensive and normotensive postpartum groups vs. non-postpartum women was an

392 unexpected finding of this study which requires validation. Although this study was not powered

393 to draw definitive conclusions about the normotensive postpartum group, these participants

demonstrated reduction in stress MBF and an "intermediate phenotype" between those with

395 preeclampsia and non-postpartum controls with respect to MFR and CVR. These findings raise

the possibility that even uncomplicated pregnancy affects coronary microcirculatory function, ahypothesis that warrants further dedicated study.

398 Fourth, studies involving advanced cardiac imaging can be adapted to the peripartum 399 period. Preterm preeclampsia was overrepresented in our cohort, partly reflecting greater 400 willingness to participate in hospital-based research among women whose preterm infants were 401 receiving care in the neonatal intensive care unit, thereby removing a key logistical barrier (need 402 for childcare) to study participation. As sFIt-1 and the sFIt-1/PIGF ratio are generally higher at 403 term than earlier in gestation even among those with preeclampsia.³⁴ it is theoretically possible 404 that the resulting gestational age imbalance served to minimize apparent differences between 405 preeclamptic and normotensive participants. This experience highlights key challenges to 406 conducting research involving new mothers and suggests potential value of protocol 407 modifications (e.g., use of vasodilators with a shorter half-life such as adenosine) to minimize 408 interruption of breastfeeding and of offering childcare or other supports to facilitate research 409 participation during a critical period when the primary focus is appropriately on caring for the 410 newborn.

411

412 Limitations

413 This study should be considered in the context of limitations. First, given the novel 414 application of PET imaging to young adults in the early postpartum period, we enrolled a sample 415 size sufficient to test differences in the primary endpoint (MFR) among those with severe 416 preeclampsia but not those with normotensive pregnancy, whose findings we expected a priori 417 to be normal. Despite the modest sample size included, significant echocardiographic 418 differences between preeclamptic and normotensive postpartum participants were detected and were consistent with the previous literature.¹³ Second, due to practical considerations of 419 420 coordinating cardiac PET imaging in newly postpartum individuals, study visits occurred at an 421 average of two weeks postpartum; differences among groups may have already partially

422 attenuated by the time of study assessments. Although strictly standardized timing of PET 423 imaging is not feasible in the newly postpartum population, timing of study visits was consistent 424 between preeclamptic and normotensive postpartum groups, and assessments across the first 425 four postpartum weeks enabled us to examine trends over time. Third, to ensure safety of 426 preeclamptic participants, we permitted participants to use antihypertensive medications prior to 427 study assessments if necessary, which may have influenced results. However, prior literature suggests these medications would be expected to have favorable effects on MFR,^{35,36} whereas 428 429 those requiring antihypertensive medication in our study had evidence of greater reduction in 430 MFR, possibly reflecting unresolved preeclampsia pathophysiology. Fourth, obstetrical history 431 was not available in the non-postpartum control cohort, although no participants in this control 432 cohort had chronic hypertension. Fifth, the postpartum groups were studied using a more recent 433 generation PET camera than non-postpartum controls. However, all PET cameras used in the 434 study were calibrated quarterly to ensure accurate activity concentration in PET images: 435 therefore, measurements of arterial and tissue activity concentrations are expected to be 436 consistent and reproducible across PET cameras. Finally, this study employed a cross-sectional 437 design, and we cannot exclude the possibility that pre-conception MFR and MBF differ in those 438 who go on to develop preeclampsia; future longitudinal studies will be required to clarify 439 lifecourse trajectories of microvascular function.

440

441 **Perspectives**

Overall, we found evidence of reduced coronary microvascular function in the
postpartum period among individuals delivering with severe preeclampsia. These observations
in humans corroborate previous findings in preclinical models and lend support to the notion that
systemic microvascular dysfunction in preeclampsia also involves the coronary microcirculation.
These findings may be relevant to preeclampsia-associated cardiovascular risk, including
increased risk of heart failure. Future research is needed to clarify lifecourse trajectories of

- 448 coronary and extracoronary microvascular function in women with preeclampsia and establish
- 449 effective interventions to mitigate risk of preeclampsia-associated cardiovascular disease.

450 Novelty and Relevance

451

452 What is New?

- Among women with severe preeclampsia undergoing cardiac positron emission
- 454 tomography perfusion imaging in the early postpartum period, myocardial flow reserve
- 455 and stress myocardial blood flow were lower, and stress coronary vascular resistance
- 456 was higher, compared with values in non-postpartum controls.
- Myocardial flow reserve appeared to recover with time following severe preeclampsia
- 458 due to normalization of rest flows; this normalization of rest flow was tightly correlated
- 459 with the sFIt-1/PIGF ratio and was independent of hemodynamics.

460

461 What is Relevant?

Our findings support the notion that systemic microvascular dysfunction in preeclampsia
 also involves the coronary microcirculation.

464

465 Clinical/Pathophysiological Implications?

- Interventions that promote microvascular health may reduce the risk of preeclampsia-
- 467 associated cardiovascular disease.
- Further research is needed to understand cardiac effects of normal pregnancy and their

469 underlying mechanisms.

470 Supplemental Material

- 471 Supplemental Methods
- 472 Figures S1-S5
- 473 Tables S1-S9

Sources of Funding: This work was supported by Massachusetts General Hospital Corrigan Women's Heart Health Program and the Brigham and Women's Hospital Cardiovascular Imaging Program. Dr. Honigberg is supported by the National Heart, Lung, and Blood Institute (NHLBI. K08HL166687) and the American Heart Association (940166, 979465). Dr. Wang is supported by the NHLBI (T32HL094301) and by the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital. Dr. Brown is supported by the NHLBI (K23HL159279) and American Heart Association (852429). Dr. Weber is supported by the NHLBI (K23HL159276) and American Heart Association (851511). Dr. Lau is supported by the NHLBI (K23HL159243) and American Heart Association (853922). Dr. Natarajan is supported by grants from the NHLBI (R01HL142711, R01HL148050, R01HL148565) and Fondation Leducg (TNE-18CVD04). Dr. Hamburg is supported by the NHLBI (R01HL160003, R01HL168889) and the American Heart Association (20SRFRN35120118). Dr. Ho is supported by the NHLBI (K24HL153669, R01HL160003). Dr. Roh is supported by the NHLBI (R01HL170048), National Institute on Aging (K76AG04328), MGH Transformative Scholars Award, and the Fred and Ines Yeatts Fund for Innovative Research. Dr. Scott receives support from the NHLBI (REBIRTH trial, NCT05180773) and from the Heart Outcomes in Pregnancy Expectations (HOPE) registry. Dr. Di Carli is supported by the NIH (R01HL162960, R01EB034586).

Disclosures: Dr. Honigberg reports consulting fees from CRISPR Therapeutics and Comanche Biopharma, advisory board service for Miga Health, and grant support from Genentech. Dr. Brown reports consulting fees from Bayer AG and AstraZeneca. Dr. Weber reports advisory board service for Novo Nordisk, Horizon Therapeutics, Kinsika Pharmaceuticals, and Aegpha. Dr. Lau reports previous advisory board service for Astellas Pharma. Dr. Natarajan reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in Preciseli and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. Dr. Hamburg reports consulting fees from Merck, Boston Scientific, and Novo Nordisk, all unrelated to the present work. Dr. Di Carli reports grant support from Gilead Sciences, in-kind research support from Amgen, and consulting fees from Sanofi, MedTrace Pharma, and Vale Health.

References

1. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia. *Circ Res.* 2019;124(7):1094-1112.

2. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;76(14):1690-1702.

3. Garovic VD, White WM, Vaughan L, et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. *J Am Coll Cardiol*. 2020;75(18):2323-2334.

4. O'Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women. *Circ Res.* 2022;130(4):652-672.

5. Honigberg MC, Zekavat SM, Aragam K, et al. Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy. *J Am Coll Cardiol*. 2019;74(22):2743-2754.

6. Honigberg MC, Riise HKR, Daltveit AK, et al. Heart Failure in Women With Hypertensive Disorders of Pregnancy: Insights From the Cardiovascular Disease in Norway Project. *Hypertension*. 2020;76(5):1506-1513.

7. Hansen AL, Søndergaard MM, Hlatky MA, et al. Adverse Pregnancy Outcomes and Incident Heart Failure in the Women's Health Initiative. *JAMA Netw Open*. 2021;4(12):e2138071.

8. Behrens I, Basit S, Lykke JA, et al. Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy. *JAMA*. 2016;315(10):1026-33.

9. Williams D, Stout MJ, Rosenbloom JI, et al. Preeclampsia Predicts Risk of Hospitalization for Heart Failure with Preserved Ejection Fraction Hospitalization. *J Am Coll Cardiol*. 2021;78(23):2281-2290.

10. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med*. 2004;350(7):672-83.

11. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest*. 2003;111(5):649-58.

12. Weissgerber TL, Milic NM, Milin-Lazovic JS, Garovic VD. Impaired Flow-Mediated Dilation Before, During, and After Preeclampsia: A Systematic Review and Meta-Analysis. *Hypertension*. 2016;67(2):415-23.

13. Vaught AJ, Kovell LC, Szymanski LM, et al. Acute Cardiac Effects of Severe Pre-Eclampsia. *J Am Coll Cardiol*. 2018;72(1):1-11.

14. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. *Nature*. 2012;485(7398):333-8.

15. Shahul S, Medvedofsky D, Wenger JB, et al. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. *Hypertension*. 2016;67(6):1273-80.

16. Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019;73(16):2106-2116.

17. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2018;72(21):2625-2641.

18. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J*. 2018;39(10):840-849.

19. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. *Obstet Gynecol.* 2019;133(1):e1-e25.

20. Giorgione V, Melchiorre K, O'Driscoll J, Khalil A, Sharma R, Thilaganathan B. Maternal echocardiographic changes in twin pregnancies with and without pre-eclampsia. *Ultrasound Obstet Gynecol*. 2022;59(5):619-626.

21. Dröge L, Herraìz I, Zeisler H, et al. Maternal serum sFlt-1/PIGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. *Ultrasound Obstet Gynecol.* 2015;45(3):286-93.

22. Di Carli MF, Afonso L, Campisi R, et al. Coronary vascular dysfunction in premenopausal women with diabetes mellitus. *Am Heart J*. 2002;144(4):711-8.
23. El Fakhri G, Kardan A, Sitek A, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-ammonia PET. *J*

Nucl Med. 2009;50(7):1062-71. 24. Goel A, Maski MR, Bajracharya S, et al. Epidemiology and Mechanisms of De Novo and

Persistent Hypertension in the Postpartum Period. *Circulation*. 2015;132(18):1726-33. 25. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015;28(1):1-39.e14.

26. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314.

27. Thadhani R, Lemoine E, Rana S, et al. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. *NEJM Evidence*. 2022;1(12).

Honigberg MC, Givertz MM. Peripartum cardiomyopathy. *BMJ*. 2019;364:k5287.
 Biwer LA, Lu Q, Ibarrola J, et al. Smooth Muscle Mineralocorticoid Receptor Promotes

Hypertension After Preeclampsia. Circ Res. 2023;132(6):674-689.

30. Honigberg MC, Zekavat SM, Raghu VK, Natarajan P. Microvascular Outcomes in Women With a History of Hypertension in Pregnancy. *Circulation*. 2022;145(7):552-554.

31. Boardman H, Lamata P, Lazdam M, et al. Variations in Cardiovascular Structure, Function, and Geometry in Midlife Associated With a History of Hypertensive Pregnancy. *Hypertension*. 2020;75(6):1542-1550.

32. Guerraty MA, Rao HS, Anjan VY, et al. The role of resting myocardial blood flow and myocardial blood flow reserve as a predictor of major adverse cardiovascular outcomes. *PLoS One*. 2020;15(2):e0228931.

33. Belfort MA, Anthony J, Saade GR, et al. The oxygen consumption/oxygen delivery curve in severe preeclampsia: evidence for a fixed oxygen extraction state. *Am J Obstet Gynecol*. 1993;169(6):1448-55.

34. Stepan H, Herraiz I, Schlembach D, et al. Implementation of the sFIt-1/PIGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. *Ultrasound Obstet Gynecol.* 2015;45(3):241-6.

Billinger M, Seiler C, Fleisch M, Eberli FR, Meier B, Hess OM. Do beta-adrenergic blocking agents increase coronary flow reserve? *J Am Coll Cardiol*. 2001;38(7):1866-71.
Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. *Hypertension*. 1996;27(5):1031-8.

Figure Legends.

Figure 1. Severe preeclampsia is associated with reduced myocardial flow reserve in the early postpartum period. (A) Myocardial flow reserve by group. (B) Difference in myocardial flow reserve among postpartum women with severe preeclampsia and normotensive postpartum women vs. non-postpartum controls. Women with severe preeclampsia (n=19) underwent PET imaging at a mean (SD) 15.3 (7.6) days postpartum; normotensive postpartum women (n=5) underwent PET imaging at 14.4 (8.4) days postpartum. Non-postpartum women (n=13) constituted the reference group. Myocardial flow reserve was significantly reduced among women following delivery with severe preeclampsia.

Figure 2. (A) Myocardial flow reserve and (B) rest myocardial blood flow vs. time following delivery among women with preeclampsia. Women with severe preeclampsia (*n*=19) underwent PET imaging at a mean (SD) 15.3 (7.6) days postpartum (overall range: 2-30 days). Myocardial flow reserve appeared to increase, and rest myocardial blood draw appeared to decrease, with time following delivery.

Figure 3. Correlation of (A) myocardial flow reserve and (B) rest myocardial blood flow with the sFIt-1/PIGF ratio among women with preeclampsia. Myocardial flow reserve was moderately inversely associated, and rest myocardial blood flow strongly positive correlated, with the sFIt-1/PIGF ratio among postpartum women with preeclampsia (*n*=19). sFIt-1 indicates soluble fms-like tyrosine kinase receptor-1. PIGF indicates placental growth factor.

	Preeclampsia, postpartum (<i>n</i> =19)	Normotensive, postpartum (<i>n</i> =5)	Non- postpartum (<i>n</i> =13)	P- value
Age at study visit	32.9 (2.8)	31.5 (3.6)	40.1 (8.5)	0.004
Race/ethnicity				
Asian	1 (5.3%)	1 (20.0%)	0 (0%)	
Black	2 (10.5%)	0 (0%)	3 (23.1%)	0.35
Hispanic	2 (10.5%)	1 (20.0%)	0 (0%)	
White	14 (73.7%)	3 (60.0%)	10 (76.9%)	
Chronic hypertension	4 (21.1%)	0 (0%)	0 (0%)	0.17
Chronic diabetes mellitus	0 (0%)	0 (0%)	0 (0%)	1
Former smoking history	4 (21.1%)	0 (0%)	0 (0%)	0.17
Within past 12 months	1 (5.3%)	0 (0%)	0 (0%)	1
History of hypertensive disorder in prior pregnancy	3 (15.8%)	0 (0%)		1
Parity	12 (63.2%)	3 (60.0%)		
• 2	4 (21.1%)	1 (20.0%)		1
• 3+	3 (15.8%)	1 (20.0%)		
Pre-pregnancy body mass	27.5	24.0		
index	[22.5, 32.6]	[20.8, 25.8]		0.14
Gestational diabetes in index pregnancy	1 (5.3%)	0 (0%)		1
Use of aspirin for preeclampsia prevention in index pregnancy	6 (31.6%)	0 (0%)		0.28
Gestational age at delivery, weeks + days	30+5 [27+6, 34+5]	39+0.5 [37+6, 39+6]		0.006
Mechanism of delivery Spontaneous vaginal Cesarean section 	1 (5.3%) 18 (94.7%)	4 (80.0%) 1 (20.0%)		0.002
Days postpartum at study visit	15.3 (7.6)	14.4 (8.4)		0.83
Body mass index at study visit	28.9 [25.8, 36.1]	22.7 [22.6, 30.9]	23.0 [22.0, 27.0]	0.009
Body mass index at study visit ≥30 kg/m ²	9 (47.4%)	2 (40.0%)	2 (15.4%)	0.20
Rest systolic blood pressure at study visit	139.2 (19.1)	104.4 (14.4)	116.0 (18.8)	<0.001
Rest diastolic blood pressure at study visit	78.4 (11.9)	62.2 (9.4)	64.9 (12.3)	0.003
Rest heart rate at study visit	73.3 (11.4)	55.6 (5.9)	70.0 (8.0)	0.004
Antihypertensive medication use on morning of study visit	8 (42.1%)	0 (0%)	0 (0%)	0.009

Table 1. Characteristics of the primary analytic cohort with cardiac positron emission tomography imaging.

participants by grou	Preeclampsia, postpartum (<i>n</i> =19)					Normotensive, postpartum (<i>n</i> =5)				Non- postpartum (<i>n</i> =13)	
	Mean (SD)	differer	Unadjusted Age-adjusted difference vs.		Mean (SD)	Unadjusted Age-ad difference vs. differen non-postpartum non-post		ce vs.	Mean (SD)		
		Beta (95% Cl)	P- value	Beta (95% Cl)	P- value		Beta (95% Cl)	P- value	Beta (95% Cl)	P- value	
Myocardial flow reserve	2.82 (0.70)	-0.67 (-1.21 to - 0.13)	0.016	-0.76 (-1.39 to -0.14)	0.018	3.14 (0.55)	-0.35 (-1.14 to 0.44)	0.37	-0.47 (-1.34 to 0.41)	0.29	3.49 (0.84)
Rest MBF, mL/min/g	0.94 (0.29)	-0.02 (-0.19 to 0.16)	0.85	0.02 (-0.17 to 0.22)	0.81	0.73 (0.18)	-0.22 (-0.47 to 0.03)	0.08	-0.17 (-0.45 to 0.11)	0.21	0.96 (0.15)
Stress MBF, mL/min/g	2.55 (0.64)	-0.68 (-1.07 to - 0.29)	0.001	-0.61 (-1.06 to -0.16)	0.01	2.23 (0.21)	-1.01 (-1.58 to - 0.43)	0.001	-0.92 (-1.56 to -0.28)	0.006	3.24 (0.43)
Rest CVR, mmHg/mL/min/g	110.9 (39.7)	23.9 (1.3 to 46.5)	0.04	22.6 (-3.7 to 48.9)	0.09	94.0 (14.8)	6.9 (-26.1 to 39.9)	0.67	5.4 (-31.6 to 42.4)	0.77	87.0 (16.0)
Stress CVR, mmHg/mL/min/g	38.2 (10.8)	12.4 (6.0 to 18.7)	<0.001	12.1 (4.7 to 19.5)	0.002	32.2 (1.9)	6.4 (-2.9 to 15.7)	0.17	6.1 (-4.3 to 16.6)	0.24	25.8 (6.2)

Table 2. Myocardial flow reserve, myocardial blood flow, coronary vascular resistance, and differences vs. non-postpartum participants by group.

MBF indicates myocardial blood flow. CVR indicates coronary vascular resistance. SD indicates standard deviation.

	Preeclampsia,	Normotensive,	P-value
	postpartum	postpartum	
	(<i>n</i> =17)	(<i>n</i> =7)	
Septal wall, mm	8.9 (2.0)	6.7 (0.4)	<0.001
Posterior wall, mm	9.1 (1.5)	6.8 (1.0)	<0.001
Relative wall thickness	0.38 (0.07)	0.30 (0.07)	0.03
LV end-diastolic dimension, mm	47.7 (4.0)	46.0 (6.2)	0.52
LV end-systolic dimension, mm	33.9 (4.3)	31.8 (4.2)	0.29
LV ejection fraction, %	57.2 (4.1)	57.8 (3.8)	0.75
LA volume, mL	55.7 (12.6)	45.5 (10.5)	0.06
Mitral E, cm/s	84.5 (13.1)	82.6 (13.7)	0.76
Mitral A, cm/s	58.1 (10.9)	51.2 (17.9)	0.37
Mitral E/A ratio	1.4 [1.4, 1.7]	2.0 [1.3, 2.0]	0.38
Lateral e', cm/s	13.7 (2.6)	16.8 (2.1)	0.009
Septal e', cm/s	11.0 (2.7)	12.2 (2.9)	0.35
Average E/e' ratio	7.8 [6.6, 8.0]	5.7 [5.0, 7.2]	0.04
Tricuspid regurgitant velocity, cm/s	1.9 (0.4)	1.7 (0.2)	0.18
Tricuspid annular S', cm/s	12.5 (2.3)	12.7 (2.2)	0.86
Tricuspid annular plane systolic excursion, cm	23.9 (4.7)	22.5 (3.7)	0.45
RV fractional age change, %	42.3 (5.3)	40.3 (5.8)	0.45
Basal LV longitudinal strain, %	-14.2 (3.1)	-16.2 (2.3)	0.10
Mid-LV longitudinal strain, %	-14.3 (3.8)	-15.5 (1.8)	0.32
Apical LV longitudinal strain, %	-14.2 (4.8)	-17.1 (4.8)	0.21
Global LV longitudinal strain, %	-14.3 (3.5)	-16.3 (2.4)	0.12

Table 3. Echocardiographic findings in postpartum participants.

Values are displayed as mean (SD) or median [IQR] for normally distributed and skewed variables, respectively. LV indicates left ventricular. RV indicates right ventricular.

Figure 1. Severe preeclampsia is associated with reduced myocardial flow reserve in the early postpartum period.

(A) Myocardial flow reserve by group. (B) Difference in myocardial flow reserve among postpartum women with severe preeclampsia and normotensive postpartum women vs. non-postpartum controls. Women with severe preeclampsia (n=19) underwent PET imaging at a mean (SD) 15.3 (7.6) days postpartum; normotensive postpartum women (n=5) underwent PET imaging at 14.4 (8.4) days postpartum. Non-postpartum women (n=13) constituted the reference group. Myocardial flow reserve was significantly reduced among women following delivery with severe preeclampsia.




Figure 2. (A) Myocardial flow reserve and (B) rest myocardial blood flow vs. time following delivery among women with preeclampsia. Women with severe preeclampsia (*n*=19) underwent PET imaging at a mean (SD) 15.3 (7.6) days postpartum (overall range: 2-30 days). Myocardial flow reserve appeared to increase, and rest myocardial blood draw appeared to decrease, with time following delivery.




Figure 3. Correlation of (A) myocardial flow reserve and (B) rest myocardial blood flow with the sFIt-1/PIGF ratio among women with preeclampsia. Myocardial flow reserve was moderately inversely associated, and rest myocardial blood flow strongly positive correlated, with the sFIt-1/PIGF ratio among postpartum women with preeclampsia (*n*=19). sFIt-1 indicates soluble fms-like tyrosine kinase receptor-1. PIGF indicates placental growth factor.

